Osiris Therapeutics to Present at the 24th Annual Piper Jaffray Healthcare Conference

  Osiris Therapeutics to Present at the 24th Annual Piper Jaffray Healthcare

Piper Jaffray Healthcare Conference 2012

Business Wire

COLUMBIA, Md. -- November 20, 2012

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company
focused on developing and marketing products to treat medical conditions in
inflammatory, cardiovascular, orthopedic and wound healing markets, announced
today that C. Randal Mills, Ph.D., President and Chief Executive Officer, is
scheduled to present at the 24^th Annual Piper Jaffray Healthcare Conference
on Tuesday, November 27, 2012 at 9:00 a.m. ET in New York City.

A live webcast of the presentation may be accessed through the Investors page
of the Company’s website at www.Osiris.com. A replay of the webcast will be
available for one week following the conference.

About Osiris Therapeutics

Osiris Therapeutics, Inc., having developed the world’s first approved stem
cell drug, Prochymal®, is the leading stem cell company. The company is
focused on developing and marketing products to treat medical conditions in
inflammatory, cardiovascular, orthopedic and wound healing markets. In
Biosurgery, Osiris currently markets Grafix® for burns and chronic wounds, and
Ovation® for orthopedic applications. Osiris is a fully integrated company
with capabilities in research, development, manufacturing and distribution of
stem cell products. Osiris has developed an extensive intellectual property
portfolio to protect the company's technology, including 51 U.S. and 154
foreign patents.

Osiris, Prochymal, Chondrogen, Grafix and Ovation are registered trademarks of
Osiris Therapeutics, Inc. More information can be found on the company's
website, www.Osiris.com. (OSIR-G)

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements include statements about our expectations, beliefs, plans,
objectives, intentions, assumptions and other statements that are not
historical facts. Words or phrases such as "anticipate," "believe,"
"continue," "ongoing," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project" or similar words or phrases, or the
negatives of those words or phrases, may identify forward-looking statements,
but the absence of these words does not necessarily mean that a statement is
not forward-looking. Examples of forward-looking statements may include,
without limitation, statements regarding any of the following: our product
development efforts; our clinical trials and anticipated regulatory
requirements, and our ability to successfully navigate these requirements; the
success of our product candidates in development; status of the regulatory
process for our biologic drug candidates; implementation of our corporate
strategy; our financial performance; our product research and development
activities and projected expenditures, including our anticipated timeline and
clinical strategy for mesenchymal stem cells and biologic drug candidates and
marketed Biosurgery products (including Prochymal®, Chondrogen®, Grafix® and
Ovation®); our cash needs; patents, trademarks and other proprietary rights;
the safety and ability of our products and potential products to treat
disease; our ability to supply a sufficient amount of our marketed products or
product candidates and, if approved or otherwise commercially available,
products to meet demand; our costs to comply with governmental regulations;
our plans for sales and marketing; our plans regarding facilities; types of
regulatory frameworks we expect will be applicable to our products and
potential products; and results of our scientific research. Forward-looking
statements are subject to known and unknown risks and uncertainties and are
based on potentially inaccurate assumptions that could cause actual results to
differ materially from those expected or implied by the forward-looking
statements. Our actual results could differ materially from those anticipated
in forward-looking statements for many reasons, including the factors
described in the section entitled "Risk Factors" in our Annual Report on Form
10-K and other Periodic Reports filed on Form 10-Q, with the United States
Securities and Exchange Commission. Accordingly, you should not unduly rely on
these forward-looking statements. We undertake no obligation to publicly
revise any forward-looking statement to reflect circumstances or events after
the date of this press release or to reflect the occurrence of unanticipated


Osiris Therapeutics, Inc.
Erica Elchin, 443-545-1834
Press spacebar to pause and continue. Press esc to stop.